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Abstract
Background: Patients with severe mental illness often suffer from disruptions in circadian rest-activity cycles,
which might partly be attributed to ongoing psychopharmacological medication. Benzodiazepines are
frequently prescribed for prolonged periods despite recommendations of only short-term usage. Melatonin, a
naturally occurring nocturnal hormone, has the potential to stabilize disrupted circadian rhythmicity. Our aim
was to investigate how prolonged-release melatonin affects rest-activity patterns in medicated patients with
severe mental illness and if benzodiazepine dose reduction is associated with changes in circadian rhythm
parameters.
Method: Data were derived from a randomized, double-blinded clinical trial with 24 weeks follow-up. Participants
were randomized to add-on treatment with prolonged-release melatonin (2 mg) or matching placebo, and usual
benzodiazepine dosage was gradually tapered. Here we report the results of 72 h of actigraphic assessment of
activity-rest cycles performed pre and post tapering. Changes in rest-activity rhythm parameters between the
melatonin and placebo group were analyzed using the univariate general linear model. Change in activity counts
per 6 h, from baseline to follow-up, in the whole sample was analyzed using paired samples t-test.
Results: A subsample of 48 patients participated in the actigraphic assessment: 20 in the melatonin group and 28
in the placebo group. Rest-activity cycles varied from regular to highly disrupted. Melatonin significantly increased
the interdaily stability and at a trend level decreased the intradaily variability compared with placebo. Benzodiazepine
dose reduction was not associated with these circadian rhythm parameters. Activity counts were generally higher
after benzodiazepine dose reduction compared with pre tapering, but differences did not reach statistical significance.
Conclusion: Our data suggest melatonin as an aid during benzodiazepine withdrawal for patients distressed by
disrupted circadian rest-activity cycles. Benzodiazepine tapering might result in diminished sedentary behavior but
further research is needed.
Trial registration: ClinicalTrials NCT01431092, clinicaltrials.gov. Registered 31 August 2011.
Keywords: Schizophrenia, Bipolar disorder, Circadian rhythms, Benzodiazepines, Discontinuation, Withdrawal,
Circadian rhythm, Randomized clinical trial
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Background
Disturbances in rest-activity cycles in schizophrenia
patients compared with healthy controls have been
reported in several small-moderate sized clinical studies
with sleep recordings lasting from one night to several
weeks [1]. Standard nocturnal polysomnographic recor-
dings evaluate sleep stages and sleep architecture, but the
obtrusive character of the technique makes it less suitable
for investigations across several days to assess circadian
rhythmicity. Additionally, polysomnography measures
sleep and is thus primarily used during nighttime. In
this context, actigraphy has been identified and evaluated
as an important tool for assessing circadian rest-activity
patterns [2, 3]. In schizophrenia patients, a highly
variable pattern of circadian rhythm disturbances have
been reported ranging from well-entrained cycles to
highly fragmented sleep/wake cycles [4]. In general, motor
activity has been found to be markedly reduced and more
monotonous in schizophrenia patients compared with
controls [1, 5]. It has been suggested that a lack of daily
routine activities and a diminished level of zeitgebers
might explain the observed rest-activity pattern disrup-
tions observed in schizophrenia patients [6], but recent
experimental evidence does not seem to support this
view [7]. The contribution of psychopharmacological
drugs to the overall picture of circadian rhythm distur-
bances have only been scarcely investigated, but there
is some evidence that antipsychotic drugs influence
circadian rhythmicity differentially [8]. In addition to
disturbed sleep wake cycles there is evidence of alter-
ation of a number of other circadian parameters in
schizophrenia including disturbed regulation of melatonin
secretion and core body temperature [9].
Benzodiazepines are frequently prescribed in chronic
psychiatric patients to treat complaints of insomnia and
anxiety. Due to the side effect burden, benzodiazepines
are only recommended for short-term use [10, 11].
However, treatment is often prolonged and subsequent
discontinuation may pose a problem due to distressing
withdrawal symptoms. Rebound insomnia may occur
during withdrawal and via this mechanism, benzodia-
zepine discontinuation might therefore affect circadian
rhythmicity. Melatonin is a naturally occurring hormone
secreted at nighttime and implicated in sleep induction
and circadian rhythm stabilization. For these reasons,
melatonin has theoretical potential as add-on medication
for facilitating benzodiazepine discontinuation and
observational data seem to suggest a possible role for
melatonin in the context of benzodiazepine withdrawal
[12, 13].
We aimed to investigate how prolonged-release
melatonin affects circadian rhythm parameters in medi-
cated patients with schizophrenia or bipolar disorder
and if benzodiazepine dose reduction is associated with
changes in motor activity and diurnal rest-activity pat-
terns. We hypothesized that treatment with melatonin
would result in a more stable circadian rest-activity
pattern compared with placebo. Furthermore, we hypo-
thesized that benzodiazepine dose reduction/disconti-
nuation would be associated with increased motor activity
due to lessened sedation and amelioration of apathy and
other negative-like symptoms.
Methods
Study design and participants
This is a single-center, randomized, double-blinded
clinical trial conducted at a university hospital research
department in the capital region of Denmark. Partici-
pants eligible for the trial were 18 years or above; had a
diagnosis of schizophrenia, schizoaffective disorder or
bipolar mood disorder (and euthymic at inclusion);
were treated with at least one antipsychotic drug and
had a daily use of at least one benzodiazepine or
benzodiazepine-like drug for a minimum of 3 months;
did not present with current violent or aggressive behav-
ior; were not diagnosed with mental retardation, pervasive
developmental disorder, dementia, hepatic impairment,
terminal illness, severe somatic comorbidity, or epilepsy;
were able to understand Danish; and were not allergic to
any compounds in the study medication. Fertile women
were only included if not pregnant or nursing and if using
safe contraceptives throughout the study period.
After baseline investigations, participants were rando-
mized to prolonged-release melatonin (PRM) 2 mg or
identical placebo once daily for 24 weeks, and in parallel
they were instructed to gradually reduce their daily benzo-
diazepine usage. Participants were instructed to ingest
the study medication approximately 2 h before bedtime
with a small meal.
The overall aim of the trial was to investigate if
PRM can facilitate discontinuation of long-term benzo-
diazepine usage in chronic psychiatric patients and these
results have been published elsewhere [14] in agreement
with CONSORT guidelines. Primary and secondary
outcomes are described in the published trial protocol
[15]. Here we report the results of actimetric assess-
ments in a subset of the participants during three
consecutive days and nights before and after 24 weeks
of benzodiazepine tapering. The presented analyses of
actimetric data were not planned in details when the
trial protocol was published [15].
Actigraphic assessment and circadian rest-activity cycle
measurement
Actigraphy does not measure sleep state and thus cannot
differentiate between sleep and sedentary behavior, but it
is established as a reliable instrument for evaluating
sleep patterns, for studying the effects of treatments to
Baandrup et al. BMC Psychiatry  (2016) 16:348 Page 2 of 8
improve sleep, and in the diagnosis of circadian rhythm
disorders [2, 3, 16]. A recent review confirmed the
clinical usefulness of actigraphy for objective evaluation
of sleep habits and circadian rhythm disturbances in
psychotic disorders [1].
We measured actimetry for three consecutive days and
nights (72 h) to evaluate rest-activity patterns with and
without melatonin and before and after benzodiazepine
tapering. From the American Academy of Sleep
Medicine it has been recommended to use at least three
consecutive days of actigraphic recording to obtain
reasonable reliability of actigraphic estimates of sleep
and 24 h rhythm activity variables [16]. The results of
one night polysomnography (at baseline and follow-up),
which was performed simultaneously with the first night
of actigraphy, will be reported elsewhere. Subjects were
asked not to change anything in day or night activities
and to continue their usual circadian patterns as
uninterrupted as possible while actimetric recordings
were done. Recordings were performed from Tuesday to
Friday or from Friday to Monday.
We used Actiwatch Spectrum (Philips Respironics)
which was continuously worn on the non-dominant
arm for a minimum of 72 h. The Actiwatch is a small
portable device, the size of a wrist-watch, which
uses an accelerometer to detect and log wrist move-
ment (Actiwatch Clinical Implementation Guide;
www.actigraphy.com).
Day and night time activity data were logged at 30 s
epochs, stored within the Actiware software (version
6.0.0, Respironics, Murrysville, PA, USA), and exported
as activity counts per 30 s. We did not use the automati-
cally displayed sleep variables except for wake up time,
which was used for alignment of activity counts. Data
were then processed to calculate activity counts per
hour and activity counts per 6 h. We analyzed activity
counts with wake up time (as opposed to clock time)
as reference. Wake up time was used as circadian
phase marker.
Actigraphic assessed circadian rest-activity cycle
parameters included the interdaily stability (IS), the
intradaily variability (IV), and the relative amplitude
(RA). These non-parametric circadian rhythm parameters
have been recommended because they more accurately
describe characteristics of disturbances in the rest-activity
rhythm and because they are more sensitive to change
compared with alternative statistical procedures [17].
The IS quantifies the invariability from day to day, i.e.,
the predictability of the 24 h rest-activity pattern. This
index will be 1 for perfect IS and thus lower values reflect
higher variability between the observed days. The IV
reflects the fragmentation of the rhythm, i.e., the frequency
and extent of transitions between rest and activity. Thus,
higher values of IV reflect higher degree of fragmentation
and more frequent shifts between rest and activity. The RA
is calculated from the ratio of the most active 10 h period
to the least active 5 h period in the average 24 h pattern
and thus higher values reflect more pronounced differences
between periods of rest and activity (typically between
day and night time). These non-parametric variables
have been used in several studies of circadian rhythm
and motor disturbances in schizophrenia [4, 5].
Statistical methods
We used SPSS version 22 for statistical analyses. All
analyses were based on complete cases for actigraphy
assessment at baseline and follow-up.
Activity counts were measured in 30 s epochs, con-
verted to 60 s epochs and entered into an excel template
for calculation of the three rest-activity rhythm para-
meters (IS, IV, and RA) across the 72 h of actigraphic
assessment at both baseline and follow-up. IS was
calculated as the ratio between the variance for the
average 24 h pattern around the mean and the overall
variance, IV was calculated as the ratio of the mean
squares of the difference between all successive hours
and the mean squares around the grand mean, and RA
was calculated from the most active 10 h period and the
least active 5 h period in the average 24 h pattern [17].
Changes in IS, IV, and RA between the PRM and placebo
group were analyzed using the univariate general linear
model with the outcome measure (24 weeks value) as
the dependent variable and the baseline value, inter-
vention group, and benzodiazepine dose reduction
(from baseline to end point) as independent variables.
In case of non-normal distributions, a non-parametric
test (Mann–Whitney U-test) was used.
For evaluation of level of activity, the activity counts
for the second recorded night and day (from midnight
to midnight) at both baseline and follow-up were
converted to number per hour and number per 6 h. We
chose the second night and day due to the best data
quality compared with the first and third night and day.
Mean activity count per hour was plotted against time
with actigraphy wake up time as reference for the total
sample. Change in activity counts per 6 h from baseline
to follow-up in the total sample as well per group was
analyzed using paired samples t-test.
Results
A subsample of 48 participants were actimetrically
evaluated: 20 in the PRM group and 28 in the placebo
group. Not all participants in the trial accepted to
participate in sleep and actigraphy recordings (not
mandatory for trial participation), which led to the
unequal numbers of participants in the groups for this
outcome. All participants were outpatients. Baseline
demographic and clinical characteristics are listed in
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Table 1. There were no statistically significant differences
between the intervention groups.
Visual inspection of individual rest-activity cycles
showed various degrees of circadian rhythmicity, from
regular to highly disrupted rest-activity patterns. We
investigated the distribution of IS, IV, and RA at baseline
and at follow-up in each intervention group. IS was
normally distributed according to visual inspection
and the Shapiro-Wilk’s test (p > 0.05). The mean IS was
0.61 (95 % CI 0.56 to 0.66) in the PRM group and
0.54 (95 % CI 0.51 to 0.58) in the placebo group at
follow-up with a mean difference between the groups
of 0.07 (95 % CI 0.01 to 0.13), which was statistically
significant (P = 0.03), when adjusting for the baseline
value in the univariate general linear model. IS was
not associated with benzodiazepine dose reduction in
the sample as a whole (respective coefficient in the
model not statistically significant, P = 0.74).
IV and RA were positively skewed and it was not pos-
sible to obtain normal distributions after transformation.
We therefore analyzed IV and RA non-parametrically
(Mann–Whitney U-test). When comparing the median
value at follow-up for IV (0.81 in the PRM group versus
1.01 in the placebo group) there was a borderline
significant difference (p = 0.06) with the lowest value
(indicating the least diurnal rhythm fragmentation) in
the melatonin group, but for RA there was no difference
between intervention groups (0.83 in both groups).
There was no correlation between benzodiazepine dose
reduction and IV (Spearman’s correlation, r =−0.052,
p = 0.79) or RA (Spearman’s correlation, r = −0.145,
p = 0.45) in the whole sample.
Figures 1 and 2 illustrate mean activity counts per
hour against time after wake up at, respectively, baseline
and follow-up. Table 2 presents activity counts per 6 h
aligned to wake up time. Activity counts generally
increased from baseline to follow-up. However, the
differences did not reach statistical significance besides a
trend during the first 6 h interval after wake up, e.g., the
beginning of the day (P = 0.063).
When looking at the intervention groups separately,
the results were consistent: there were no statistically
significant differences between baseline and follow-up
when comparing each of the 6 h intervals (Table 3).
Discussion
This is the first study investigating changes in rest-
activity patterns in a psychiatric population tapered from
chronic benzodiazepine use covered by melatonin versus
placebo. We found that melatonin stabilized circadian
rest-activity rhythmicity by significantly increasing the IS
and at a trend level reducing the IV compared with
placebo. Benzodiazepine dose reduction was associated
with statistically insignificant increases in daytime and
nighttime activity counts, and benzodiazepine dose
reduction was not correlated with changes in circadian
rhythm parameters.
Few studies have investigated circadian rhythmicity
objectively in patients with severe mental illness,
particularly in relation to clinical trials aiming to
evaluate a specific treatment of sleep or circadian rhythm
disturbances. Actually, most clinical insomnia trials
have excluded participants with psychiatric comorbidity.
Melatonin has previously been evaluated in two clinical
trials with schizophrenia patients, but not with a specific
focus on stabilization of circadian rhythm disturbances.
Shamir et al. [18] reported an improvement with mela-
tonin add-on in actimetry-derived sleep efficiency with an
effect size of 0.4 in a randomized, blinded, cross-over
clinical trial in schizophrenia patients complaining of poor
sleep quality and diagnosed with insomnia. However,
this was a small trial with only 19 participants and no
measure of rest-activity pattern. Kumar and colleagues
conducted a randomized, placebo-controlled, double-
blind clinical trial investigating the efficacy of 15 days
flexibly dosed melatonin in 40 schizophrenia outpatients
[19]. Improvement was found in several self-assessed
sleep-parameters with the clinically most relevant being
an increase in sleep duration, but no objective sleep or
activity assessment was performed. In a randomized
clinical trial of 83 euthymic bipolar patients, treatment
with ramelteon (a melatonin receptor agonist) markedly
reduced relapse rate (emergence of depressed or manic
episode) throughout the 24-week treatment period, but
again objective sleep or activity assessments were lacking
[20]. Our findings of circadian stabilization with melatonin
treatment should be further investigated, but indicate
that melatonin might be a valuable treatment option for
patients with severe mental illness distressed by disrupted
rest-activity patterns. Supporting this suggestion is experi-
mental evidence indicating severe circadian misalignment
in melatonin cycles in a substantial proportion of
patients with schizophrenia [7] together with observations
of a comprised sleep-promoting action of endogenous
melatonin in schizophrenia [21].
The implications of normalized versus disturbed
circadian rest-activity patterns has been demonstrated
on several levels. Bromundt et al. recently conducted a
study of 14 patients with schizophrenia who were actime-
trically assessed for 3 weeks and found that participants
with a normal rest-activity cycle performed better in
frontal lobe function tasks [4]. A similar conclusion was
reached in a study of 28 schizophrenia patients under-
going 3 days of actigraphy [22], where patients with
more disturbed sleep and less robust circadian rhythms
performed more poorly on neuropsychological tests.
For patients with bipolar disorder, it has been suggested
that disrupted circadian sleep-wake cycles contribute to
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relapse [23]. However, the direction of the association
between circadian disturbances and symptom level
needs further exploration and might be bidirectional
or, alternatively, reflecting different expressions of
the same underlying neuropathological disturbances.
Suggested mechanisms of circadian rhythm impairment in
schizophrenia include genetic mutations associated with
both schizophrenia and circadian regulation [24] and
inherent neurotransmitter dysfunctions associated with
schizophrenia that also disrupt mechanisms of sleep/wake
regulation in the brain stem [25]. A differential role
of antipsychotics have been reported [5, 8], but circadian
rhythm disruptions are also present in un-medicated
patients [26]. Evidence suggests that antipsychotics
ameliorate rather than impair sleep disturbances [27, 28],
whereas the influence of antipsychotics and other
psychotropics on rest-activity cycles has only been
scarcely studied [26]. To our knowledge, the influence
of benzodiazepine dose reduction/discontinuation on
circadian rest-activity cycles has not previously been
investigated. Our findings of increased motor activity,
albeit not statistically significant, with benzodiazepine
dose reduction is interpreted as reflecting a diminished
level of sedation due to reduced or discontinued benzo-
diazepine use. One should be aware that increased motor
activity during nighttime might indicate insomnia.
However, since the non-significant increase in motor
activity was dispersed throughout the day and night it
seems more plausible that the finding reflects an increase
in spontaneous motor activity.
One limitation of our study is the limited duration of
actigraphic recording. We chose the minimum recom-
mended duration of 3 days [17] to increase acceptability,
but other evidence points to the fact that a longer period
of recording is required to reduce the variability and
increase the reliability of obtained measures [18]. Due
to logistic reasons, it was not possible to obtain all
actimetric recordings during the same days of the week.
Table 1 Baseline demographic and clinical characteristics
Prolonged-release melatonin
N = 20
Placebo
N = 28
N % N %
Men 11 55.0 18 64.3
Diagnosis
Paranoid schizophrenia 15 75.0 23 82.1
Non-paranoid
schizophrenia
0 0 2 7.1
Schizoaffective disorder 2 10.0 0 0
Bipolar affective disorder 3 15.0 3 10.7
Housing
Living independently 17 85.0 19 67.8
Supported housing 1 5.0 0 0
Institution 2 10.0 9 32.1
Occupational status
Employed 0 0 0 0
Financial aid/
cash subsidies
0 0 2 7.1
Disability pension 18 90.0 44 91.7
Other 2 10.0 2 4.2
Benzodiazepine treatment
One drug 15 75.0 22 78.6
Two drugs 5 25.0 6 21.4
Clonazepam 11 55.0 30 62.5
Diazepam 0 0 1 2.0
Oxazepam 5 25.0 9 18.8
Nitrazepam 2 10.0 4 8.3
Lorazepam 0 0 1 2.1
Zopiclone 2 10.0 2 4.2
Zolpidem 0 0 1 3.6
Antipsychotic drug treatment
One drug 12 60.0 13 46.4
Two drugs 7 35.0 11 39.3
≥ Three drugs 1 5.0 14 14.3
Antidepressant drug treatment
≥One drug 14 70.0 14 50.0
Mood stabilizer drug treatment
≥One drug 6 30.0 7 25.0
Anticholinergic drug treatment
One drug 1 5.0 7 25.0
Mean SD Mean SD
Age, years 47.7 8.2 45.9 10.3
Duration of illness, years 23.3 12.7 18.9 8.1
PANSS total score 61.1 15.2 64.5 12.5
Table 1 Baseline demographic and clinical characteristics
(Continued)
Benzodiazepine treatment
duration, years
11.3 9.1 11.6 7.2
Benzodiazepine total dose,
mg diazepam equivalents
25.1 24.3 25.5 14.1
Total antipsychotic dose,
mg olanzapine equivalents
17.7 11.5 27.6 25.2
IS 0.63 0.10 0.57 0.10
IV 0.74 0.21 0.85 0.26
RA 0.85 0.10 0.87 0.09
PANSS positive and negative syndrome scale, IS interdaily stability, IV intradaily
variability, RA relative amplitude
No statistically significant differences (p < 0.05) between groups at baseline
(categorical variables evaluated with chi-square test and continuous variables
evaluated with independent t-test)
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Fig. 1 Activity counts at baseline. Legend: Mean activity counts aligned to wake up time (=0) measured the second day and night for the total
sample at baseline
Fig. 2 Activity counts at follow-up. Legend: Mean activity counts aligned to wake up time (=0) measured the second day and night for the total
sample at follow-up
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For some participants recordings were done during
weekdays and for other participants recordings were
done during the weekend. This might have influenced
the results because of different patterns and levels of
activity during weekdays compared with weekend
days. However, all the participants were unemployed
and thus did not report much difference in activity
pattern between weekdays and weekend days. Another
limitation regarding the evaluation of effect of benzo-
diazepine dose reduction on the 24 h activity pattern
is the lack of a control group continuing usual benzo-
diazepine consumption, but this was not considered
feasible due to the range of side effects associated
with continued benzodiazepine usage. The majority of
participants in this study were diagnosed with schizo-
phrenia and in the complete case sample (30 patients
undergoing actigraphy both at baseline and at follow-
up), 75% (25 patients) of the patients had a diagnosis
of schizophrenia and 25 % (5 patients) were diagnosed
with bipolar disorder. Circadian rhythm disturbances
in bipolar patients are most pronounced during episodes
of mania or depression, but inter episode disturbances in
sleep and circadian rhythmicity also exist and have been
reported to more closely resemble sleep disturbances in
insomnia patients than in healthy controls [23]. Since
sleep and circadian rhythm disturbances are also highly
prevalent in patients with schizophrenia [27] and since all
bipolar patients, who underwent actigraphic assessment,
were euthymic throughout the study period, we found it
relevant to analyze the diagnostic categories together.
Overall, due to the limited sample size the study had a
lack of power to detect more subtle differences between
intervention groups. Another obvious limitation is that
18 participants out of 40 did not participate in actigraphic
assessment at follow-up, which may have hampered the
external validity of the results. This was not necessarily
identical with drop out from the overall study aim (benzo-
diazepine dose reduction), but many of the participants
were reluctant to repeat the sleep examinations at
follow-up, even if they were given the opportunity of
only repeating actigraphy and not the polysomnographic
recordings. When analyzing the complete case sample and
the sample with sleep-activity recordings only at baseline,
no statistically significant differences appeared indicating
that the patients not completing the activity recordings at
follow-up were not markedly different from the complete
cases.
A clear advantage of our study, compared with other
studies evaluating circadian rhythm disturbances in
severely ill patients, is the randomized controlled design.
Most other studies of actimetric evaluation in schizo-
phrenia patients were cross-sectional and without
assessing effects of any intervention.
Conclusions
Add-on treatment with PRM seems to stabilize circadian
rest-activity cycles in patients with schizophrenia or bipolar
disorder, which is in line with theoretical assumptions of
melatonin activity. Benzodiazepine dose reduction might
be associated with increased daytime and nighttime motor
activity but further research is needed.
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